share_log

Goldman Sachs Maintains Neutral on Bioventus, Lowers Price Target to $2.5

Benzinga Real-time News ·  Nov 30, 2022 08:32

Goldman Sachs analyst Amit Hazan maintains Bioventus (NASDAQ:BVS) with a Neutral and lowers the price target from $13 to $2.5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment